Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2− advanced/metastatic breast cancer: updated systematic review

AimSince 2021, additional real-world evidence (RWE) has emerged on the effectiveness of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) as first-line treatment of HR-positive/HER2-negative (HR+/HER2−) advanced/metastatic breast cancer (A/MBC), necessitating this updated review.MethodsMEDLINE®, Emba...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Nadia Harbeck, Adam Brufsky, Chloe Grace Rose, Beata Korytowsky, Connie Chen, Krista Tantakoun, Endri Jazexhi, Do Hoang Vien Nguyen, Meaghan Bartlett, Imtiaz A. Samjoo, Timothy Pluard
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-03-01
Subjects:	CDK4/6 inhibitors quality assessment breast metastasis real-world evidence systematic literature review
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1530391/full